Karina Yurievna Sagamonova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Karina Yurievna Sagamonova has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Svetlana Vitalievna Lomteva
Southern Federal University
4 shared publications - Tatiana Pavlovna Shkurat
Южный федеральный университет, Ростов-на-Дону, Россия
4 shared publications - Anzhela Aslanovna Aleksandrova
Southern Federal University, Rostov-on-Don, Russia
3 shared publications - Manar Noor Aldeen Ammar
Southern Federal University, Rostov-on-Don, Russia
3 shared publications - Ruba Mohamad Ali
Southern Federal University, Rostov-on-Don, Russia
3 shared publications - Olga V. Lyangasova
Southern Federal University, Rostov-on-Don, Russia
2 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 27 (1) , 84
The involvement of polymorphisms in the MALAT1 and NEAT1 lncRNA genes in PCOS etiology
Background: Hormonal imbalance and metabolic inefficiency are hallmarks of the common complicated endocrine condition known as polycystic ovary syndrome (PCOS). Long non-coding RNAs (lncRNAs) have emerged as critical regulators of gene expression and cellular processes in various diseases, including PCOS. This study aims to investigate the relationship between specific polymorphisms in the lncRNA genes MALAT1 (rs3200401) and NEAT1 (rs674485) and the likelihood of developing PCOS. A case-control study was conducted involving PCOS women and control undergoing in vitro fertilization (IVF) at the Center for Human Reproduction and IVF in Rostov-on-Don, Russia. Genotyping was conducted using an allele-specific real-time PCR approach. Results: Our results suggest a possible association between MALAT1 rs3200401 and increased PCOS risk at the allelic level. While the difference observed in the GA genotype of NEAT1 rs674485 did not reach statistical significance and required confirmation in larger cohorts. In addition, deviation from the Hardy–Weinberg equilibrium was observed in control groups, which may reflect sample size limitations or population-specific effects. Bioinformatic analyses indicated that both variants may potentially influence the lncRNA secondary structure and microRNA binding sites; however, these findings are computational predictions and require experimental validation. Conclusion: These findings underscore the potential of MALAT1 and NEAT1 genetic variants as biomarkers and therapeutic targets in PCOS.
- 28 September 2026
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 27 (1) , 84
Open AccessThe involvement of polymorphisms in the MALAT1 and NEAT1 lncRNA genes in PCOS etiology
Background: Hormonal imbalance and metabolic inefficiency are hallmarks of the common complicated endocrine condition known as polycystic ovary syndrome (PCOS). Long non-coding RNAs (lncRNAs) have emerged as critical regulators of gene expression and cellular processes in various diseases, including PCOS. This study aims to investigate the relationship between specific polymorphisms in the lncRNA genes MALAT1 (rs3200401) and NEAT1 (rs674485) and the likelihood of developing PCOS. A case-control study was conducted involving PCOS women and control undergoing in vitro fertilization (IVF) at the Center for Human Reproduction and IVF in Rostov-on-Don, Russia. Genotyping was conducted using an allele-specific real-time PCR approach. Results: Our results suggest a possible association between MALAT1 rs3200401 and increased PCOS risk at the allelic level. While the difference observed in the GA genotype of NEAT1 rs674485 did not reach statistical significance and required confirmation in larger cohorts. In addition, deviation from the Hardy–Weinberg equilibrium was observed in control groups, which may reflect sample size limitations or population-specific effects. Bioinformatic analyses indicated that both variants may potentially influence the lncRNA secondary structure and microRNA binding sites; however, these findings are computational predictions and require experimental validation. Conclusion: These findings underscore the potential of MALAT1 and NEAT1 genetic variants as biomarkers and therapeutic targets in PCOS.
- Open Access
- 29 March 2026
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 27 (1)
Genotyping FSHR and LHCGR genes enhances prediction accuracy of unexpected poor ovarian response in normo-prognosis women undergoing IVF
Purpose: The aim of the research was to study the association of FSHR rs6166 and LHCGR rs2293275 genetic variants, and their gene-gene interactions, with poor ovarian response in women with normal prognosis based on the POSEIDON criteria, to enable personalized prediction of treatment outcomes. Materials and methods: We conducted a retrospective cohort study, including 146 relatively healthy women with normal ovulation who underwent their first IVF/ICSI cycle using a short GnRH‑antagonist protocol. All participants in the study, according to the POSEIDON criteria, had sufficient prestimulation ovarian reserve parameters (antral follicle count (AFC) ≥ 5, anti-Mullerian hormone (AMH) ≥ 1.2 ng/ml). Women with anovulation and polycystic ovary syndrome (PCOS) were excluded from the study. Results: The study identified a combined genotype that represents the absence of both (rs6166 and rs2293275) protective homozygous (AA) genotypes and is associated with more than twofold increased risk of a poor ovarian response. The combined genotype FSHR rs6166 AG/GG + LHCGR rs2293275 AG/GG have been identified as risk factor for a poor ovarian response in women with normal prognosis based on the POSEIDON criteria. The study found that among women with a normal prognosis, 75% of unexpected poor responders carried the risk genotype. The number of metaphase II (MII) oocytes retrieved was statistically significantly lower in individuals carried the risk genotype, compared to other patients. Besides, the FSHR rs6166 GG genotype has been shown to be statistically significantly associated with elevated serum FSH and progesterone levels, compared to the A allele ( AA + AG genotypes) carriers. The LHCGR rs2293275 GG genotype carriers had lower number of antral follicles and MII oocytes, compared to the A allele ( AA + AG genotypes) carriers. Conclusion: A combined assessment of POSEIDON criteria and FSHR / LHCGR genotyping can help reduce the risk of unexpected poor response in patients with a normal prognosis.
- 29 March 2026
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 27 (1)
Open AccessGenotyping FSHR and LHCGR genes enhances prediction accuracy of unexpected poor ovarian response in normo-prognosis women undergoing IVF
Purpose: The aim of the research was to study the association of FSHR rs6166 and LHCGR rs2293275 genetic variants, and their gene-gene interactions, with poor ovarian response in women with normal prognosis based on the POSEIDON criteria, to enable personalized prediction of treatment outcomes. Materials and methods: We conducted a retrospective cohort study, including 146 relatively healthy women with normal ovulation who underwent their first IVF/ICSI cycle using a short GnRH‑antagonist protocol. All participants in the study, according to the POSEIDON criteria, had sufficient prestimulation ovarian reserve parameters (antral follicle count (AFC) ≥ 5, anti-Mullerian hormone (AMH) ≥ 1.2 ng/ml). Women with anovulation and polycystic ovary syndrome (PCOS) were excluded from the study. Results: The study identified a combined genotype that represents the absence of both (rs6166 and rs2293275) protective homozygous (AA) genotypes and is associated with more than twofold increased risk of a poor ovarian response. The combined genotype FSHR rs6166 AG/GG + LHCGR rs2293275 AG/GG have been identified as risk factor for a poor ovarian response in women with normal prognosis based on the POSEIDON criteria. The study found that among women with a normal prognosis, 75% of unexpected poor responders carried the risk genotype. The number of metaphase II (MII) oocytes retrieved was statistically significantly lower in individuals carried the risk genotype, compared to other patients. Besides, the FSHR rs6166 GG genotype has been shown to be statistically significantly associated with elevated serum FSH and progesterone levels, compared to the A allele ( AA + AG genotypes) carriers. The LHCGR rs2293275 GG genotype carriers had lower number of antral follicles and MII oocytes, compared to the A allele ( AA + AG genotypes) carriers. Conclusion: A combined assessment of POSEIDON criteria and FSHR / LHCGR genotyping can help reduce the risk of unexpected poor response in patients with a normal prognosis.
- Open Access
- 26 October 2024
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 25 (1) , 1-10
FSHB and FSHR genes variants in combination with hormones levels predict low and high ovarian response to controlled ovarian stimulation: a logistic regressive model
Background: Predicting the number of follicles obtained after controlled ovarian stimulation (COS) is challenging, especially considering individual variability. Since FSH is a fundamental hormone that controls growing follicle activity, genetic variants are predicted to affect ovarian response to stimulation. The aim of the study: The purpose of this study was to analyze whether FSHB rs10835638 and FSHR rs6166 genetic variants in combination with clinical parameters might be considered as potential precise predictors of ovarian response during COS. Materials and methods: The present study included 144 women from infertile couples who underwent assisted reproductive technologies. Women with reduced FSH and/or AMH serum levels were excluded from the study. Genotyping was carried out applying restriction fragment length polymorphism analysis. Results: Genotypes frequencies for FSHB rs10835638 and FSHR rs6166 were GG (73%), GT (24%), TT (3%) and AA (42%), AG (39%), GG (19%), respectively. FSHR rs6166 GG genotype was shown as associated with higher early follicular phase serum FSH, LH and progesterone levels, compared to AA and AG genotypes. Logistic regressive models that simultaneously use the patient’s genetic and clinical characteristics to calculate the probability of low or high ovarian response have been developed. Conclusion: The present study suggests that rs10835638 and rs6166 genetic variants affect hypothalamic-pituitary–gonadal hormones serum levels, and together may provide an improved model for predicting an ovarian response during COS.
- 26 October 2024
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 25 (1) , 1-10
Open AccessFSHB and FSHR genes variants in combination with hormones levels predict low and high ovarian response to controlled ovarian stimulation: a logistic regressive model
Background: Predicting the number of follicles obtained after controlled ovarian stimulation (COS) is challenging, especially considering individual variability. Since FSH is a fundamental hormone that controls growing follicle activity, genetic variants are predicted to affect ovarian response to stimulation. The aim of the study: The purpose of this study was to analyze whether FSHB rs10835638 and FSHR rs6166 genetic variants in combination with clinical parameters might be considered as potential precise predictors of ovarian response during COS. Materials and methods: The present study included 144 women from infertile couples who underwent assisted reproductive technologies. Women with reduced FSH and/or AMH serum levels were excluded from the study. Genotyping was carried out applying restriction fragment length polymorphism analysis. Results: Genotypes frequencies for FSHB rs10835638 and FSHR rs6166 were GG (73%), GT (24%), TT (3%) and AA (42%), AG (39%), GG (19%), respectively. FSHR rs6166 GG genotype was shown as associated with higher early follicular phase serum FSH, LH and progesterone levels, compared to AA and AG genotypes. Logistic regressive models that simultaneously use the patient’s genetic and clinical characteristics to calculate the probability of low or high ovarian response have been developed. Conclusion: The present study suggests that rs10835638 and rs6166 genetic variants affect hypothalamic-pituitary–gonadal hormones serum levels, and together may provide an improved model for predicting an ovarian response during COS.
- Open Access
- 28 June 2024
- Published by Belgorod National Research University in RESEARCH RESULTS IN BIOMEDICINE
- Vol. 10 (2) , 292-302
Differential expression of CYP19A1 and lncRNA-CTBP1-AS in the granulosa cells of women with polycystic ovary syndrome
Background: Hyperandrogenism is the basic indicator of polycystic ovarian syndrome (PCOS) and a ...
- 28 June 2024
- Published by Belgorod National Research University in RESEARCH RESULTS IN BIOMEDICINE
- Vol. 10 (2) , 292-302
Open AccessDifferential expression of CYP19A1 and lncRNA-CTBP1-AS in the granulosa cells of women with polycystic ovary syndrome
Background: Hyperandrogenism is the basic indicator of polycystic ovarian syndrome (PCOS) and a ...